Skip to content

BIONCISE

Active Public limited companyfounded 2017active for 9 yearsBodemstraat 16, 3830 WellenKBO/BCE: BE 0671.983.435 subsidiary of

Lifetime

8 annual accounts with figures on one time axis
peak of €343,943 in 2021
€125,449▼ 23.5%
lowest -€240,698 in 2022
-€29,476▼ €56,243
peak of €296,673 in 2021
€172,478▼ 14.6%
€70,290▲ 9.0%
peak of 2.7 FTE in 2018
-not published
Board3 names since 2017
3 directors and 2 others
Owners
  
Documentsfilings and deeds
13-07-202618 days before the deadline
2025micro format
Gross margin from €163,961 to €125,449Loss of €29,476Registered office moved to Wellen 04-03Equity from €201,954 to €172,478Cash from €41,389 to €68,841

Key points

from the 2025 annual accounts

Equity

€172,478 from €296,673 in 2021

Equity fell by 42% in 4 years.

Result

-€29,476 -€29,476
€26,8002024-€29,5002025

From profit to loss in 2025, after a profit of €26,767 in 2024.

Position in the sector

-€29,476

Lower net result than 92% of companies in other manufacturing. The sector median is €7,187, over 839 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 3,600 companies had the same profile as BIONCISE has now. Each dot stands for 9 companies, two years later.

87.2%
were still trading
9.7%
stopped another way
3.0%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 30% or more
  • a loss of 10% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,600 companies, not a prediction for BIONCISE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Chair
Director
Director
  • 67.67%score equity €47,305 (2025) · annual accounts 2021 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0671983435
Registered office moved to Wellen The registered office moved to Bodemstraat 16/3, 3830 Wellen · , and reappointed · appointed as managing director · General meeting of 27-02-2025 · Gazette deed
changes role from director to managing director and chair of the board appointed as director · General meeting of 10-08-2020 · Gazette deed
resigns as director General meeting of 13-12-2018 · Gazette deed
All 20 events

Comparable companies

same main activity, similar in size and age
Company
BIONCISE Wellen €242,768 €125,449 71.0% -
LOVARIA DENTAL Le Roeulx €212,290 €128,925 44.1% -
JDENTAL Etterbeek €208,863 €144,981 55.0% -
Olivier Loyens Management Riemst €224,396 €138,374 63.1% -
LC LAB La Louvière €276,778 €164,808 52.3% -
Dental Labo Leyman Kruisem €206,427 €174,561 90.7% -
LUNETIER LUDOVIC Brussels €274,550 €175,535 2.4% -

These companies have the same main activity as BIONCISE: manufacture of medical and dental instruments and supplies (NACE 32500). They are comparable in size and age: total assets between €206,000 and €277,000, founded between 2015 and 2019.

Official details

Source: KBO
Status
Active since 02-03-2017Normal situation
Activity
Manufacture of medical and dental instruments and suppliesNACE 32500and 3 others
Establishment unit
2.262.452.1503830 Wellen, since 02-03-2017
Financial year end
31 December
Peppol
Reachable since 07-01-2026
Company details

Annual accounts 2025

≈ €310,000estimated
€242,768▼ 8.9%
Employeeson 31-12-2025
2=
Filing
Filed on 13-07-2026, 18 days before the end of the filing period
Financials

Insights on BIONCISE

BIONCISE files the micro format. That format states no turnover. The gross margin fell from €153,580 in 2018 to €125,449 in 2025.

holds 67.67% of the shares. In March 2025, the Official Gazette published the appointment of as managing director.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about BIONCISE

What is the company number of BIONCISE?
The company number of BIONCISE is 0671.983.435. The VAT number is the same number with BE in front: BE 0671.983.435.
Where is BIONCISE based?
The registered office is at Bodemstraat 16, 3830 Wellen.Company details
What does BIONCISE do?
According to the KBO register, the main activity is manufacture of medical and dental instruments and supplies (NACE 32500).
What is the legal form of BIONCISE?
BIONCISE is a public limited company (NV).
When was BIONCISE founded?
BIONCISE was founded on 02-03-2017.
Is BIONCISE still active?
Yes, BIONCISE is an active enterprise in the KBO register.
How many employees does BIONCISE have?
BIONCISE had an average of 2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of BIONCISE?
The turnover in financial year 2025 is about €310,000. This figure is estimated from the gross margin of €125,449 and 2,451 comparable companies of the same size. It probably lies between €210,000 and €480,000. It is a rough estimate.
Is BIONCISE profitable?
In financial year 2025, BIONCISE made a loss of €29,476.
Where can I find the annual accounts of BIONCISE?
BIONCISE filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BIONCISE due?
BIONCISE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.